FIGURE 2.

Administration of tanimilast (total daily doses of 1,600 or 3,200 μg) to COPD patients with a chronic bronchitis phenotype on top of inhaled triple therapy (ICS, LABA and LAMA) results in a broad anti-inflammatory profile in the airways associated with limited systemic effects. Figure objects were adapted by RexxS, Public domain, DataBase Center for Life Science (DBCLS), CC BY 4.0 <https://creativecommons.org/licenses/by/4.0>, and Artwork by Holly Fischer, CC BY 3.0 <https://creativecommons.org/licenses/by/3.0>, via Wikimedia Commons.